



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## PROTAC EZH2 Degradator-2

Cat. No.:	HY-157164
Molecular Formula:	C <sub>77</sub> H <sub>93</sub> Cl <sub>2</sub> N <sub>13</sub> O <sub>12</sub>
Molecular Weight:	1463.55
Target:	PROTACs; Histone Methyltransferase
Pathway:	PROTAC; Epigenetics
Storage:	4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (68.33 mM; Need ultrasonic)			
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg
				5 mg
				10 mg
				10 mM
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 3.75 mg/mL (2.56 mM); Clear solution			

### BIOLOGICAL ACTIVITY

Description	PROTAC EZH2 Degradator-2 (compound E-3P-MDM2), an EZH2 inhibitor, is a PROTAC composed of Tazemetostat (EPZ6438) and an E3 ligase system ligand. PROTAC EZH2 Degradator-2 degrades EZH2 in SU-DHL-6 cells in a dose-dependent manner, inhibits the expression of H3K27me3, and simultaneously degrades EED and SUZ12 proteins without affecting their mRNA levels. PROTAC EZH2 Degradator-2 has anti-cancer and anti-proliferative activity <sup>[1]</sup> .
IC <sub>50</sub> & Target	EZH2 <sup>[1]</sup>

### REFERENCES

[1]. Xie H et al. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma. *Bioorg Chem.* 2023 Nov;140:106762.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA